12:00 AM
 | 
Aug 13, 2007
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 8/10 cls
Acadia (ACAD) Piper Jaffray Edward Tenthoff Price target Market outperform 10% $16.40
Tenthoff raised his target to $23 from $21 after the company's 2Q07 earnings showed an R&D spend of $10.8M, below his $13M estimate. Also, this year he expects the company to partner its Pimavanserin tartrate (ACP-103), a small molecule serotonin (5-HT2A) receptor inverse agonist, which has completed a Phase IIb trial to treat schizophrenia (see BioCentury, March 26).
Axcan (TSX:AXP; AXCA) BMO Capital Markets Christine Charette Upgrade

Read the full 547 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >